Clinical Trials Logo

Filter by:
NCT ID: NCT06119802 Recruiting - Atrial Fibrillation Clinical Trials

Prediction of UA/SOD Ratio as a Biomarker of Oxidative Stress in Atrial Fibrillation

Start date: January 1, 2022
Phase:
Study type: Observational

To clarify the predictive effects of uric acid and superoxide dismutase as biomarkers of oxidative stress on atrial fibrillation, and to provide greater value for the diagnosis and prediction of atrial fibrillation. It provides a new idea for the prevention and treatment of atrial fibrillation.

NCT ID: NCT06119581 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

SUNRAY-01
Start date: December 21, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.

NCT ID: NCT06119490 Recruiting - Clinical trials for Toxic Epidermal Necrolysis

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

TEN
Start date: July 5, 2023
Phase: Early Phase 1
Study type: Interventional

To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis

NCT ID: NCT06119256 Recruiting - Clinical trials for EBV Infection After Allogenic HSCT

Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT

Start date: August 1, 2023
Phase: Phase 1
Study type: Interventional

This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of EBV-TCR-T cell immunotherapy in treating EBV virus infection after allogenic HSCT.

NCT ID: NCT06119022 Recruiting - Clinical trials for Treatment Decision, Coronary Artery Disease

CT Myocardial Perfusion to Guide the Diagnosis and Treatment of Patients With Stable Coronary Artery Disease (POTENTIAL)

Start date: September 30, 2023
Phase: N/A
Study type: Interventional

The overall goal of this project is to compare the non-revascularization rate of coronary angiography in patients with stable coronary artery disease (CAD) within 90 days after CT myocardial perfusion imaging (CT-MPI) or Single-Photon Emission Computed Tomography myocardial perfusion imaging (SPECT-MPI), and 1-year major adverse cardiovascular events (MACE).

NCT ID: NCT06118866 Recruiting - Clinical trials for Androgenetic Alopecia

A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

Start date: September 11, 2023
Phase: Phase 2
Study type: Interventional

To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks

NCT ID: NCT06118788 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Start date: March 7, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-arm, single-dose dose-escalation and dose-expansion study.

NCT ID: NCT06118762 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer

Start date: October 20, 2023
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of Fruquintinib combined with Raltitrexed in the treatment of metastatic colorectal cancer that progressed or could not be tolerated after previous fluorouracil, oxaliplatin, and irinotecan based therapy

NCT ID: NCT06118450 Recruiting - STEMI Clinical Trials

Clinical Trial for Evaluating the Effectiveness and Safety of Online caIMR in STEMI Patients

FlashIV
Start date: November 1, 2023
Phase:
Study type: Observational

Despite the success of restoration of epicardial blood flow by the primary percutaneous coronary intervention (PPCI), approximately a half of patients with ST-segment elevation myocardial infarction (STEMI) have failed myocardial reperfusion, as reflected by microvascular obstruction (MVO) and intramyocardial haemorrhage (IMH). The coronary angiography-derived index of microvascular resistance (caIMR) is a brand new method for assessing coronary microcirculation in ischemia and no obstructive coronary artery disease (INOCA). In this trial, the investigators aim to verify the safety and effectiveness of caIMR in STEMI who underwent primary PCI. The investigators will immediately measure the caIMR of patients who successfully underwent pPCI, and combine the caIMR with the long-term prognosis, to verify the prognostic performance of caIMR.

NCT ID: NCT06118333 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Start date: December 4, 2023
Phase: Phase 3
Study type: Interventional

A phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic nasopharyngeal carcinoma who had failed at least two lines of platinum-based chemotherapy after receiving PD-1/PD-L1 monoclonal antibody as the last line of therapy.